Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00497380
Other study ID # 81167
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date April 2009
Est. completion date February 2021

Study information

Verified date April 2019
Source Texas A&M University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Muscle catabolism is a major problem in cancer patients undergoing surgery as it negatively affects post-operative recovery. Recent evidence exists that protein metabolic changes are already apparent in cancer before muscle wasting is being present. In line, patients with breast cancer, generally characterized by a normal nutritional status, were recently found to be arginine deficient. Arginine deficiency in cancer can be explained by: 1) Reduced arginine availability, due to exhaustion of endogenous (muscle) sources of arginine 2) Enhanced arginine catabolism, due to conversion of arginine by arginase, which is abundant in tumors. Protein is the most important endogenous source of arginine. Arginine deficiency will lead to a negative feedback loop in cachexia by promoting protein breakdown in an attempt to restore plasma arginine levels. We hypothesize that pre-operative arginine supplementation in breast cancer patients diminishes the occurrence of muscle wasting after surgery by 1) normalizing arginine availability pre-operatively, resulting in conservation of protein, 2) diminishing the catabolic effects of surgery by supplying exogenous arginine for the post-operative response, 3) enhancing the anabolic capacity to feeding through supplying substrate for protein synthesis.


Description:

In the present proposal, the effects of surgery and cancer will be examined by comparing subjects undergoing breast surgery because of malignancy vs. prophylactic reasons (aim 1). Furthermore, the effects of one-week pre-operative protein feeding with or without enrichment with arginine on post-operative protein metabolism (aim 2) will be investigated in the cancer group. Variables of interest are: 1. Whole-body and skeletal muscle protein metabolism, whole body arginine turnover and de-novo arginine production rate, and the anabolic capacity to feeding(assessed by stable isotope methodology). 2. Body weight, muscle mass and functional status, score for well-being (assessed by Profile of Mood State and Mini Mental State).

In the present study, we propose that a nutritional supplement that is high in protein content and enhanced in arginine will be more effective than a typical commercial nutritional supplement in diminishing the catabolic effects of surgery in subjects with cancer, thereby optimizing their quality of life. If this is found to be the case, this would provide the basis for reformulating the nutritional composition in accord with the effects of cancer and surgery on protein metabolism.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 32
Est. completion date February 2021
Est. primary completion date July 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 30 Years and older
Eligibility Inclusion Criteria:

Cancer groups (for aims 1 and 2)

1. Recently diagnosed (up to 4 weeks prior to treatment for cancer) with stage I, II or III invasive breast cancer

2. Undergoing mastectomy

3. Age greater than 30 years

4. Ability to sign informed consent

5. Good performance status defined by ECOG scale 0,1 or 2 (see CRF performance status)

Control group (for aim 1)

1. Age greater than 30 years

2. Undergoing prophylactic mastectomy

3. Ability to sign informed consent

4. Good performance status defined by ECOG scale 0,1 or 2 (see CRF performance status)

Exclusion Criteria:

All groups (aim 1 and 2)

1. Body weight loss of greater than 10% in the past 3 months

2. Previous anti-cancer therapy (e.g. chemotherapy or radiotherapy) or surgery less than 4 weeks prior to the experiment

3. Diagnosed diabetes type I or II

4. Untreated metabolic diseases including liver or renal disease

5. Any documented autoimmune disease

6. Use of corticosteroids, beta-antagonists or nitrovasodilators

7. Use of supplements enriched with amino acids

8. Presence of acute illness or metabolically unstable chronic illness

9. Unstable heart disease requiring therapy or recent myocardial infarction (less than 1 year)

10. Current alcohol or drug abuse (ETOH more than 2 servings per day)

11. Allergy/intolerance to any of the ingredients of the study products

12. Any other condition deemed by the PI and the study physician as exclusion or that interferes with proper conduct of the study/ safety of the patient.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Arginine
Oral nutritional supplement

Locations

Country Name City State
United States University of Arkansas for Medical Sciences Little Rock Arkansas

Sponsors (1)

Lead Sponsor Collaborator
Texas A&M University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Net protein balance end of study
Secondary Arginine turnover end of study
See also
  Status Clinical Trial Phase
Completed NCT01143493 - The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease
Active, not recruiting NCT01461603 - Local Effects of Amino Acids and 3-hydroxybutyrate in the Bilaterally Perfused Human Leg N/A
Completed NCT04422665 - Preventing Bed-rest Induced Muscle Loss in the Elderly N/A
Completed NCT04121689 - Time Course of Postprandial Protein Metabolism N/A
Completed NCT01820702 - Short Term Bed Rest Study: Evaluation of the Use of Artificial Gravity, Induced by Short-arm Centrifugation N/A
Completed NCT03142737 - Are the "Ounce-equivalents" in the Protein Foods Groups Really Equivalent? N/A
Completed NCT03952884 - Skeletal Muscle Protein Synthetic Response to Amino Acid and Peptides N/A
Completed NCT05197140 - Role of the Protein Matrix in the Anabolic Response to a Ground Beef Patty as Opposed to the Impossible (Vegi-) Burger N/A
Completed NCT04821557 - Effect of Microbial Protease Supplementation on Postprandial Amino Acid Levels N/A
Recruiting NCT05400733 - Prandial Metabolic Phenotype in Adults N/A
Terminated NCT00586807 - Metabolic Response to Infliximab in Pediatric Ulcerative Colitis N/A
Completed NCT01276795 - Whey Protein-based Enteral Nutrition Support to Improve Protein Economy in Surgical Patients N/A
Completed NCT00586352 - Protein Metabolism in Newly Diagnosed Pediatric Inflammatory Bowel Disease N/A
Completed NCT03037294 - Protein Turnover in the Osteoarthritic Knee N/A
Completed NCT01509456 - The Effect of Potassium Bicarbonate on Bone and Several Physiological Systems During Immobilisation N/A
Completed NCT00583232 - Protein and Energy Metabolism in Pediatric Crohn's Disease Phase 1
Completed NCT03179462 - "Ounce-equivalents" in the Protein Foods Group: Benefits of Quality N/A
Completed NCT03326284 - Optimal Protein Dose Per Meal During Weight Loss in Perspective to Maintaining Muscle Mass N/A
Completed NCT03147001 - Protein Ingestion Before Training Low N/A